Corden Pharma - A Full-Service CDMO in the news

Dr. Jean-Luc Herbeaux has been appointed as the new Group Chief Executive Officer of CordenPharma.

CordenPharma appointed Jean-Luc Herbeaux as CEO to lead its next growth phase, succeeding Michael Quirmbach.

Marc Augustin joins the Swiss CDMO CordenPharma as Chief Financial Officer following his tenure at PolyPeptide.

The peptide therapeutics CDMO market is experiencing significant growth, driven by GLP-1 peptides and increasing outsourcing preference, with a projected market value of USD 9.0 billion by 2036.

CordenPharma Colorado leased a 64,000 sqft purpose-built lab at BioMed Realty's Flatiron Park to expand its peptide development and analytical services.

CordenPharma Colorado is expanding its peptide development lab with a 15-year lease at BioMed Realty's Flatiron Park, enhancing its manufacturing and development capabilities in Boulder.

CordenPharma Colorado leased a new 64,000 sq ft lab space at Flatiron Park to expand peptide development and manufacturing capabilities.

CordenPharma Colorado is expanding its peptide development lab with a 64,000 sq ft lease at BioMed Realty's Flatiron Park, enhancing its capabilities and supporting Boulder’s life science growth.

In 2025, CDMOs globally expanded manufacturing capacity in sterile fill-finish, peptides, and biologics, with CordenPharma investing over $1 billion in peptide production growth.

The U.S. pharmaceutical CDMO market is rapidly growing due to biologics and outsourcing trends, with small molecules and APIs leading revenue and oncology as the top therapeutic area.

CordenPharma's CEO Michael Quirmbach has been named a finalist for CEO of the Year at the CPHI Pharma Awards 2025.

The peptide and oligonucleotide CDMO market is rapidly expanding with major investments from CordenPharma and others to increase manufacturing capacity and support growing drug development.

Several pharmaceutical CDMOs including Lonza, Corden Pharma, Fujifilm Diosynth, Thermo Fisher, and SK Pharmteco announced major expansions and investments to increase manufacturing capacity and technology capabilities.

A new €500 million peptide manufacturing facility near Basel, Switzerland, will expand production capacity and create over 300 jobs by 2028.

CordenPharma is investing €1 billion to build a new peptide manufacturing plant in Switzerland and expand its Colorado site, aiming to boost production capacity and sales by 2028.

CordenPharma has entered a long-term agreement to manufacture Viking Therapeutics' GLP-1 drug candidate in both injectable and oral forms.

CordenPharma and Viking Therapeutics signed a multi-year partnership for manufacturing and supply of Viking's GLP-1 drug candidate VK2735, covering peptide production, injectables, and oral formulations.

CordenPharma is building a $540 million peptide manufacturing plant in Switzerland to boost GLP-1 production, part of a larger strategic investment.

CordenPharma is investing over ‱500 million to build a new peptide manufacturing facility in Switzerland, creating over 300 jobs and expanding its production capacity for peptide medicines by early 2028.

The Lipid Nanoparticles CDMO Market, focusing on Nucleic Acids LNPs, is projected to grow significantly by 2030, driven by increased interest in mRNA and nanoparticle medical applications, with Corden Pharma expanding its lipid purification capacity.